Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Work In Process (2024 - 2026)

Syndax Pharmaceuticals (SNDX) has disclosed Work In Process for 3 consecutive years, with $2.9 million as the latest value for Q1 2026.

  • For Q1 2026, Work In Process rose 401.57% year-over-year to $2.9 million; the TTM value through Mar 2026 reached $2.9 million, up 401.57%, while the annual FY2025 figure was $2.1 million, 540.0% up from the prior year.
  • Work In Process hit $2.9 million in Q1 2026 for Syndax Pharmaceuticals, up from $2.1 million in the prior quarter.
  • Across five years, Work In Process topped out at $2.9 million in Q1 2026 and bottomed at $330000.0 in Q4 2024.
  • Average Work In Process over 3 years is $1.4 million, with a median of $1.3 million recorded in 2025.
  • Year-over-year, Work In Process skyrocketed 540.0% in 2025 and then skyrocketed 401.57% in 2026.
  • Syndax Pharmaceuticals' Work In Process stood at $330000.0 in 2024, then surged by 540.0% to $2.1 million in 2025, then skyrocketed by 35.84% to $2.9 million in 2026.
  • According to Business Quant data, Work In Process over the past three periods came in at $2.9 million, $2.1 million, and $1.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.